Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis

BACKGROUND & AIMS: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are heterogeneous neoplasms. Although some have a relatively benign and indolent natural history, others can be aggressive and ultimately fatal. Somatostatin analogues (SSAs) improve both quality of life and survival for...

Descripción completa

Detalles Bibliográficos
Autores principales: Rustgi, Sheila D., Oh, Aaron, Yang, Jeong Yun, Kang, Dasol, Wolin, Edward, Kong, Chung Y., Hur, Chin, Kim, Michelle K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146685/
https://www.ncbi.nlm.nih.gov/pubmed/34030646
http://dx.doi.org/10.1186/s12885-021-08306-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146685/
https://www.ncbi.nlm.nih.gov/pubmed/34030646
http://dx.doi.org/10.1186/s12885-021-08306-5

Ejemplares similares